Protalix BioTherapeutics
Develops and manufactures plant-cell-derived enzyme therapies for rare diseases.
$2.58
After-hours close+0.05 (+1.87%)
At close$2.54(−2.87%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 20.93%Insiders —
Shares outstanding 80.57M · Float 77.45M · 96.1% free float
Institutions13F, as of Mar 31, 2026
106 holders · 16.86M shares · 28 new positions · 55 increased · 21 reduced · 9 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 3.62M | 4.49% | −30.1K | May 13, 2026 |
| Mak Capital One LLC | 3.54M | 4.40% | +3.54Mnew | May 15, 2026 |
| Renaissance Technologies LLC | 1.22M | 1.52% | −38.5K | May 14, 2026 |
| State Street Corp | 972.8K | 1.21% | +387.6K | May 15, 2026 |
| Northern Trust Corp | 885.4K | 1.10% | +19.7K | May 14, 2026 |
| Geode Capital Management, LLC | 865.3K | 1.07% | +35.2K | May 15, 2026 |
| Stratos Wealth Partners, Ltd. | 500.0K | 0.62% | 0 | Apr 28, 2026 |
| Vanguard Portfolio Management LLC | 432.5K | 0.54% | +432.5Knew | May 8, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 5.02% | 4.05M | 13G | Jul 29, 2026 ↗ |
InsidersForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.